2/2 NCCU-LCCC Partnership in Cancer Research

2/2 NCCU-LCCC 癌症研究合作伙伴关系

基本信息

  • 批准号:
    9548165
  • 负责人:
  • 金额:
    $ 100.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-28 至 2020-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant) Abstract: The North Carolina Central University (NCCU) and the Lineberger Comprehensive Cancer Center (LCCC) at the University of North Carolina Chapel Hill (UNC-CH) will continue their effective and mutually beneficial partnership focusing on African-American health disparities. During the past 13 years NCI funding has firmly established the Partnership building on complementary institutional strengths, conducting molecular and population-based cancer research and training of junior faculty and students. This Comprehensive Partnership to Advance Cancer Health Equity (CPACHE) application builds upon the foundation already established through the previous U54 funding to meet the challenge of disparities in cancer incidence and mortality in North Carolina and the US through cancer research, education and community outreach. Our goals are to: (1) strengthen cancer research capacity at NCCU providing NCCU scientists mentorship and collaborative opportunities to compete for NCI grants; (2) enrich the capacity of NCCU and LCCC to further explore mechanisms underlying the disproportionate incidence of cancer mortality and morbidity between African Americans and Caucasian Americans, using both molecular and population-based approaches; (3) increase the number of NCCU scientists focused on cancer research as well as the education of minority undergraduate and graduate students in cancer research; (4) increase the faculty at the UNC LCCC focused on minority disparities research; and (5) create long-term collaborations between basic, public health, and translational scientists from NCCU and UNC LCCC. The strengths of each institution are uniquely positioned to overcome the weaknesses found in the other to achieve these priorities. Specific collaborative components of the proposal include: Two full and one pilot projects in community intervention and population science, one full and one pilot project in basic/translational cancer research in diseases with a higher incidence in African Americans, and 3 cores: Outreach, Research Education, and Histopathology. The partnership combines the expertise and resources of LCCC in population/public health sciences emphasizing disparities in North Carolina, genomics, cancer biology and cancer education and NCCU's demonstrated interest and faculty with minority health disparities research particularly in Durham NC, the state-funded NCCU units that allow faculty release from teaching and the emphasis on reaching minority populations and developing the careers of, faculty and students. These complementary institutional strengths will assure that the Partnership builds the infrastructure necessary for a lasting collaborative research, effective community outreach and a substantial contribution to our understanding of minority disparities.
简介(由申请者提供)摘要:北卡罗来纳中央大学(NCCU)和北卡罗来纳大学教堂山分校(UNC-CH)的莱恩伯格综合癌症中心(LCCC)将继续致力于非裔美国人健康差距的有效和互利的合作伙伴关系。在过去的13年里,NCI的资助建立了牢固的伙伴关系,建立在互补的机构优势之上,开展基于分子和人群的癌症研究,并对初级教职员工和学生进行培训。这项促进癌症健康公平的全面伙伴关系(CPACHE)应用程序建立在通过之前的U54基金建立的基础上,通过癌症研究、教育和社区推广,应对北卡罗来纳州和美国癌症发病率和死亡率差异的挑战。我们的目标是:(1)加强NCCU的癌症研究能力,为NCCU的科学家提供导师和合作机会,以竞争NCI拨款;(2)丰富NCCU和LCCC的能力,以进一步探索非裔美国人和高加索美国人之间癌症死亡率和发病率不成比例的机制,使用分子和基于人群的方法;(3)增加NCCU专注于癌症研究的科学家数量以及对少数族裔本科生和研究生的癌症研究教育;(4)增加NCCU的教员,专注于少数族裔差异研究;以及(5)在NCCU和UNC LCCC的基础、公共卫生和翻译科学家之间建立长期合作关系。每个机构的优势都具有独特的优势,可以克服彼此的弱点,从而实现这些优先事项。该提案的具体合作部分包括:社区干预和人口科学方面的两个完整项目和一个试点项目,非裔美国人中发病率较高的疾病的基础/转化性癌症研究一个完整项目和一个试点项目,以及三个核心:外联、研究教育和组织病理学。这一合作伙伴关系结合了LCCC在人口/公共卫生科学方面的专业知识和资源,强调北卡罗来纳州的差异、基因组学、癌症生物学和癌症教育,以及NCCU对少数族裔健康差异研究表现出的兴趣和兴趣,特别是在北卡罗来纳州的Durham,这是国家资助的NCCU单位,允许教师从教学中解脱出来,强调接触少数族裔人口和发展教师和学生的职业生涯。这些相辅相成的体制优势将确保伙伴关系建立必要的基础设施,以便开展持久的合作研究、有效地开展社区宣传,并为我们对少数群体差距的理解作出重大贡献。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

H. Shelton Earp其他文献

A Calcium-dependent Tyrosine Kinase Splice Variant in Human Monocytes
人单核细胞中钙依赖性酪氨酸激酶剪接变体
  • DOI:
  • 发表时间:
    1998
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Xiong Li;Deborah Hunter;John S. Morris;J. Stephen Haskill;H. Shelton Earp
  • 通讯作者:
    H. Shelton Earp
Colorectal adenocarcinomas have increased EGFR ligand expression
  • DOI:
    10.1016/j.jamcollsurg.2006.05.219
  • 发表时间:
    2006-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Abigail S. Caudle;Laura Caskey;H. Shelton Earp;Benjamin Calvo
  • 通讯作者:
    Benjamin Calvo
TAM family kinases as therapeutic targets at the interface of cancer and immunity
TAM 家族激酶作为癌症与免疫相互作用界面的治疗靶点
  • DOI:
    10.1038/s41571-023-00813-7
  • 发表时间:
    2023-09-04
  • 期刊:
  • 影响因子:
    82.200
  • 作者:
    Deborah DeRyckere;Justus M. Huelse;H. Shelton Earp;Douglas K. Graham
  • 通讯作者:
    Douglas K. Graham
Exploiting structural variability in the kinase back-pocket to modulate polypharmacology of TAM inhibitors
利用激酶后袋的结构变异性来调节TAM抑制剂的多药理学特性
  • DOI:
    10.1016/j.ejmech.2025.117561
  • 发表时间:
    2025-06-05
  • 期刊:
  • 影响因子:
    5.900
  • 作者:
    Megan D. Hopkins;Dehui Zhang;Zhilong Chen;Andrew L. McIver;Justus M. Huelse;Jyoti P. Mahajan;Kaikai Lyu;Xiangbo Yang;Michael A. Stashko;Brittany Smith;Tsz Y. Yeung;H. Shelton Earp;Stephen V. Frye;Deborah DeRyckere;Dmitri Kireev;Douglas K. Graham;Xiaodong Wang
  • 通讯作者:
    Xiaodong Wang
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
TAM 家族:在癌症中出错的磷脂酰丝氨酸感应受体酪氨酸激酶
  • DOI:
    10.1038/nrc3847
  • 发表时间:
    2014-11-24
  • 期刊:
  • 影响因子:
    66.800
  • 作者:
    Douglas K. Graham;Deborah DeRyckere;Kurtis D. Davies;H. Shelton Earp
  • 通讯作者:
    H. Shelton Earp

H. Shelton Earp的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('H. Shelton Earp', 18)}}的其他基金

Divergent Roles of MerTK,Tyro3, and Axl in Pancreatic Cancer and Metastasis
MerTK、Tyro3 和 Axl 在胰腺癌和转移中的不同作用
  • 批准号:
    10601958
  • 财政年份:
    2022
  • 资助金额:
    $ 100.39万
  • 项目类别:
MerTK and the Innate Immune Response to Melanoma
MerTK 和对黑色素瘤的先天免疫反应
  • 批准号:
    9231607
  • 财政年份:
    2017
  • 资助金额:
    $ 100.39万
  • 项目类别:
ADMINISTRATION (Admin Core)
管理(管理核心)
  • 批准号:
    9316431
  • 财政年份:
    2016
  • 资助金额:
    $ 100.39万
  • 项目类别:
Senior Leadership
高层领导
  • 批准号:
    8720100
  • 财政年份:
    2013
  • 资助金额:
    $ 100.39万
  • 项目类别:
Ack1: Activation and Consequences in Prostate Cancer
Ack1:前列腺癌中的激活和后果
  • 批准号:
    8270330
  • 财政年份:
    2011
  • 资助金额:
    $ 100.39万
  • 项目类别:
Ack1: Activation and Consequences in Prostate Cancer
Ack1:前列腺癌中的激活和后果
  • 批准号:
    8193120
  • 财政年份:
    2011
  • 资助金额:
    $ 100.39万
  • 项目类别:
Developmental Funds
发展基金
  • 批准号:
    8340172
  • 财政年份:
    2011
  • 资助金额:
    $ 100.39万
  • 项目类别:
Senior Leadership
高层领导
  • 批准号:
    8340155
  • 财政年份:
    2011
  • 资助金额:
    $ 100.39万
  • 项目类别:
Planning and Evaluation
规划与评估
  • 批准号:
    8340169
  • 财政年份:
    2011
  • 资助金额:
    $ 100.39万
  • 项目类别:
NCCU-LCCC Partnership in Cancer Research (2 of 2)
NCCU-LCCC 癌症研究合作伙伴关系(2 of 2)
  • 批准号:
    8329650
  • 财政年份:
    2010
  • 资助金额:
    $ 100.39万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了